Hengrui Medicine (600276.SH): Clinical trial of HRS-7172 tablet drug approved

Zh tng cijng APP xn, hng ru y yo (600276.SH) gnggo, gngs shudo guji yopn jind gunl j hk zhnf guny HRS-7172 pin de "yow lnchng shyn p zhn tngzhsh", tngy bn pn dnyo zi xidi RAS tbin hu kuzhng de wnq shtlio hunzh zhng kizhn lnchng shyn. HRS-7172 pin sh gngs zzh ynf de xnxng kng zhngy xio fnz zhzhj. According to the latest news from the Wisdom Financial APP, Hengrui Medicine (600276.SH) announced that the company has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for HRS-7172 tablets, approving the clinical trial of this drug in patients with advanced solid tumors carrying RAS mutations or amplifications. HRS-7172 tablets are a new type of anti-tumor small molecule inhibitor independently developed by the company.